Drug
Chf10067
Chf10067: highest development phase Phase 2, developed by Chiesi Farmaceutici. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Chiesi Farmaceutici
Trials
| Drug | Phase | Indication |
|---|---|---|
| CHF10067 NCT07516951 | Phase 2 | Idiopathic Pulmonary Fibrosis |
Latest
No recent events.
Follow Chf10067 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.